Albireo Pharma, Inc. (NASDAQ:ALBO) insider Pamela Stephenson sold 451 shares of the firm’s stock in a transaction that occurred on Monday, September 27th. The stock was sold at an average price of $32.05, for a total transaction of $14,454.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
NASDAQ ALBO traded down $0.45 during trading hours on Tuesday, hitting $31.50. 119,246 shares of the company traded hands, compared to its average volume of 195,719. Albireo Pharma, Inc. has a twelve month low of $27.23 and a twelve month high of $43.41. The stock has a market capitalization of $606.56 million, a price-to-earnings ratio of -4.29 and a beta of 1.46. The business’s 50-day moving average is $29.97 and its 200-day moving average is $32.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.23 and a current ratio of 7.23.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.92) by $0.02. Albireo Pharma had a negative return on equity of 82.94% and a negative net margin of 1,468.41%. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.60 million. Analysts predict that Albireo Pharma, Inc. will post -6.13 EPS for the current year.
A number of analysts have recently issued reports on ALBO shares. Zacks Investment Research cut Albireo Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, September 21st. Robert W. Baird increased their price objective on Albireo Pharma from $67.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, July 22nd. HC Wainwright reiterated a “buy” rating and set a $79.00 price target on shares of Albireo Pharma in a research report on Wednesday, September 8th. Finally, Wedbush raised their price objective on Albireo Pharma from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, September 16th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat, Albireo Pharma currently has an average rating of “Buy” and an average price target of $79.60.
Albireo Pharma Company Profile
Albireo Pharma, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat.
Featured Article: Green Investing
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.